FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006446835> ?p ?o ?g. }

• W2006446835 endingPage "100" @default.
• W2006446835 startingPage "88" @default.
• W2006446835 abstract "Objective To evaluate the efficacy and safety of AVP ‐825, a drug–device combination of low‐dose sumatriptan powder (22 mg loaded dose) delivered intranasally through a targeted B reath P owered device vs an identical device containing lactose powder (placebo device) in the treatment of migraine headache. Background Early treatment of migraine headaches is associated with improved outcome, but medication absorption after oral delivery may be delayed in migraineurs because of reduced gastric motility. Sumatriptan powder administered with an innovative, closed‐palate, B i‐ D irectional, B reath P owered intranasal delivery mechanism is efficiently absorbed across the nasal mucosa and produces fast absorption into the circulation. Results from a previously conducted placebo‐controlled study of AVP ‐825 showed a high degree of headache relief with an early onset of action (eg, 74% AVP ‐825 vs 38% placebo device at 1 hour, P < .01). Methods In this double‐blind, placebo‐controlled, parallel‐group study in adults with a history of migraine with or without aura, participants were randomized via computer‐generated lists to AVP ‐825 or placebo device to treat a single migraine headache of moderate or severe intensity. The primary endpoint was headache relief (defined as reduction of headache pain intensity from severe or moderate migraine headache to mild or none) at 2 hours post‐dose. Results Two hundred and thirty patients (116 AVP ‐825 and 114 placebo device) were randomized, of whom 223 (112 and 111, respectively) experienced a qualifying migraine headache (their next migraine headache that reached moderate or severe intensity). A significantly greater proportion of AVP ‐825 patients reported headache relief at 2 hours post‐dose compared with those using the placebo device (68% vs 45%, P = .002, odds ratio 2.53, 95% confidence interval [1.45, 4.42]). Between‐group differences in headache relief were evident as early as 15 minutes, reached statistical significance at 30 minutes post‐dose (42% vs 27%, P = .03), and were sustained at 24 hours (44% vs 24%, P = .002) and 48 hours (34% vs 20%, P = .01). Thirty‐four percent of patients treated with AVP ‐825 were pain‐free at 2 hours compared with 17% using the placebo device ( P = .008). More AVP ‐825 patients reported meaningful pain relief (patient interpretation) of migraine within 2 hours of treatment vs placebo device (70% vs 45%, P < .001), and fewer required rescue medication (37% vs 52%, P = .02). Total migraine freedom (patients with no headache, nausea, phonophobia, photophobia, or vomiting) reached significance following treatment with AVP ‐825 at 1 hour (19% vs 9%; P = .04). There were no serious adverse events ( AEs ), and no systemic AEs occurred in more than one patient. Chest pain or pressure was not reported, and only one patient taking AVP ‐825 reported mild paresthesia. No other triptan sensations were reported. Conclusions Targeted delivery of a low‐dose of sumatriptan powder via a novel, closed‐palate, B reath P owered, intranasal device ( AVP ‐825) provided fast relief of moderate or severe migraine headache in adults that reached statistical significance over placebo by 30 minutes. The treatment was well tolerated with a low incidence of systemic AEs ." @default.
• W2006446835 created "2016-06-24" @default.
• W2006446835 creator A5018094103 @default.
• W2006446835 creator A5053109281 @default.
• W2006446835 creator A5059824642 @default.
• W2006446835 creator A5063293385 @default.
• W2006446835 creator A5065018970 @default.
• W2006446835 creator A5077352083 @default.
• W2006446835 creator A5084396069 @default.
• W2006446835 date "2014-10-30" @default.
• W2006446835 modified "2023-10-18" @default.
• W2006446835 title "A Randomized, Double‐Blind, Placebo‐Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder ( <scp>AVP</scp> ‐825) in the Treatment of Acute Migraine (The <scp>TARGET</scp> Study)" @default.
• W2006446835 cites W1514386258 @default.
• W2006446835 cites W1975039706 @default.
• W2006446835 cites W1981954594 @default.
• W2006446835 cites W1994848292 @default.
• W2006446835 cites W1995350344 @default.
• W2006446835 cites W2004261781 @default.
• W2006446835 cites W2005128914 @default.
• W2006446835 cites W2010836203 @default.
• W2006446835 cites W2015642877 @default.
• W2006446835 cites W2016981603 @default.
• W2006446835 cites W2017344242 @default.
• W2006446835 cites W2018340655 @default.
• W2006446835 cites W2020276316 @default.
• W2006446835 cites W2028159603 @default.
• W2006446835 cites W2030192874 @default.
• W2006446835 cites W2034436548 @default.
• W2006446835 cites W2045511561 @default.
• W2006446835 cites W2045670750 @default.
• W2006446835 cites W2046465426 @default.
• W2006446835 cites W2048386518 @default.
• W2006446835 cites W2053973584 @default.
• W2006446835 cites W2056227040 @default.
• W2006446835 cites W2060214014 @default.
• W2006446835 cites W2062036940 @default.
• W2006446835 cites W2072679041 @default.
• W2006446835 cites W2073110936 @default.
• W2006446835 cites W2080328086 @default.
• W2006446835 cites W2081374067 @default.
• W2006446835 cites W2083120125 @default.
• W2006446835 cites W2098988727 @default.
• W2006446835 cites W2126194551 @default.
• W2006446835 cites W2128838967 @default.
• W2006446835 cites W2132309748 @default.
• W2006446835 cites W2132805893 @default.
• W2006446835 cites W2137782989 @default.
• W2006446835 cites W2143573177 @default.
• W2006446835 cites W2145077191 @default.
• W2006446835 cites W2167411996 @default.
• W2006446835 doi "https://doi.org/10.1111/head.12472" @default.
• W2006446835 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4320758" @default.
• W2006446835 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25355310" @default.
• W2006446835 hasPublicationYear "2014" @default.
• W2006446835 type Work @default.
• W2006446835 sameAs 2006446835 @default.
• W2006446835 citedByCount "46" @default.
• W2006446835 countsByYear W20064468352015 @default.
• W2006446835 countsByYear W20064468352016 @default.
• W2006446835 countsByYear W20064468352017 @default.
• W2006446835 countsByYear W20064468352018 @default.
• W2006446835 countsByYear W20064468352019 @default.
• W2006446835 countsByYear W20064468352020 @default.
• W2006446835 countsByYear W20064468352021 @default.
• W2006446835 countsByYear W20064468352022 @default.
• W2006446835 countsByYear W20064468352023 @default.
• W2006446835 crossrefType "journal-article" @default.
• W2006446835 hasAuthorship W2006446835A5018094103 @default.
• W2006446835 hasAuthorship W2006446835A5053109281 @default.
• W2006446835 hasAuthorship W2006446835A5059824642 @default.
• W2006446835 hasAuthorship W2006446835A5063293385 @default.
• W2006446835 hasAuthorship W2006446835A5065018970 @default.
• W2006446835 hasAuthorship W2006446835A5077352083 @default.
• W2006446835 hasAuthorship W2006446835A5084396069 @default.
• W2006446835 hasBestOaLocation W20064468351 @default.
• W2006446835 hasConcept C126322002 @default.
• W2006446835 hasConcept C141071460 @default.
• W2006446835 hasConcept C142724271 @default.
• W2006446835 hasConcept C170493617 @default.
• W2006446835 hasConcept C204787440 @default.
• W2006446835 hasConcept C27081682 @default.
• W2006446835 hasConcept C2777119127 @default.
• W2006446835 hasConcept C2778541695 @default.
• W2006446835 hasConcept C2778871607 @default.
• W2006446835 hasConcept C2778938600 @default.
• W2006446835 hasConcept C2780564907 @default.
• W2006446835 hasConcept C2780966972 @default.
• W2006446835 hasConcept C42219234 @default.
• W2006446835 hasConcept C71924100 @default.
• W2006446835 hasConcept C85663871 @default.
• W2006446835 hasConcept C98274493 @default.
• W2006446835 hasConceptScore W2006446835C126322002 @default.
• W2006446835 hasConceptScore W2006446835C141071460 @default.
• W2006446835 hasConceptScore W2006446835C142724271 @default.
• W2006446835 hasConceptScore W2006446835C170493617 @default.
• W2006446835 hasConceptScore W2006446835C204787440 @default.
• W2006446835 hasConceptScore W2006446835C27081682 @default.
• W2006446835 hasConceptScore W2006446835C2777119127 @default.

• next